BioWorld-International-2002-09-25
KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy
KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy
LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International)

